Dong-A Pharmaceutical signs exclusive supply deal with Neuain for migraine relief device

Dong-A Pharmaceutical signed an exclusive domestic supply agreement with Neuain on June 13, 2023, for a migraine relief medical device. The wearable device, which received FDA 510K and CE-MDD certification, will be exclusively sold by Dong-A in South Korea.

“동아제약은 13일 서울 동대문구 용두동 동아제약 본사에서, 전자약 연구개발 전문 기업 뉴아인과 편두통 완화 의료기기의 국내 독점 판매 공급 계약을 체결했다.”newswire.co.kr

• 1 source
• newswire.co.kr동아제약, 뉴아인과 편두통 완화 의료기기 국내 독점 판매 공급 계약 체결 - 뉴스와이어동아제약Jun 14, 2023

Summarized from public sources; check the original articles before acting on it.